PMC7768838_01
Left: 18F-FDG-PET/CT scan in August 2018 showed pleural extramedullary disease (EMD) and focal bone lesions of the right femur. "Pom-PAD-Dara" (pomalidomide, bortezomib, doxorubicin, dexamethasone, daratumumab) had been initiated 2 days prior to imaging and therefore, we observed a significant reduction of EMD metabolism. Right: 18F-FDG-PET/CT scan in August 2019 demonstrated therapy response after nine cycles of "Pom-PAD-Dara".
10.1177_2058738420980258-fig1.jpg
PMC7768838_01_10.1177_2058738420980258-fig1.jpg
fig1-2058738420980258
Of note, under therapy, the patient suffered from serological and extramedullary progression with pleural manifestation (Figure 1). She achieved serological sCR with minimal residual disease (MRD) negativity at a sensitivity level of 10-5, and whole body 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) scan showed a significant reduction of both medullary and extramedullary lesions with only minimal activity detected (Figure 1). Supplemental Figures S1 and S2 displayed the Ig A and free lambda light chain level in the entire course of the disease, respectively.